drugset
drugset / Trial / NCT06190561

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

NCT06190561 ↗

Phase 1 Completed 40 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-07940367 once by mouth. The participants may receive different tablets by mouth for PF-07940367. The study will compare experiences of people receiving two different products of PF-07940367. This will help understand how much PF-07940367 is taken up into the blood for each product given. Participants will take part in the study for about 112 days. During this time, participants will have to stay onsite for 5 days. There will be up to 2 additional onsite study visits and 3 remote (telephone call) study visits.

Timeline

Start
2024-01-15
Primary completion
2024-05-07
Completion
2024-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Osivelotor Small molecule 150 mg Oral

Indications

No indication recorded.